Paris and Boston, April 30, 2025 – 9:15 p.m. CEST – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary...
Publication of the 2024 Annual Financial Report
read more
Search Results
Mauna Kea Technologies Announces Another Milestone Year at Digestive Disease Week® 2025 with 8 Presentations Demonstrating the Clinical Value of Cellvizio® in Key Indications
Pancreatic cyst abstracts build on endorsement of Cellvizio® by Europe’s leading endoscopy society, ESGE, as a key tool for improving pancreatic...
Mauna Kea Technologies Reports Full Year 2024 Results and Provides a Business Update
Commercial activities remain strong, including CellTolerance® launch Recently approved safeguard proceeding yielding productive creditor and...
Mauna Kea Technologies announces entrance into exclusive negotiations for a licensing agreement for Cellvizio® in an important therapeutic area with a major industry player
The Company also confirms that it is pursuing licensing discussions in other therapeutic areas The protective framework of the safeguard...
Mauna Kea Technologies announces the opening of a safeguard proceeding to restructure its financial liabilities
The aim of the procedure is to optimize the Company's financial structure in order to adapt it to the needs of its future growth The...
Cellvizio® Now Recommended in New European Society of Gastrointestinal Endoscopy Technical Guideline for Pancreatic Cyst Diagnosis
ESGE, Europe’s leading endoscopy society, endorses Cellvizio® as a key tool for improving pancreatic cyst diagnostic accuracy, marking a major step...
Mauna Kea Technologies Announces Promising Results in New Application Combining Robotics and Cellvizio® for Precision Surgery in Head and Neck Cancers
Cellvizio was successfully integrated into TransOral Robotic Surgery (TORS) procedures to assess peripheral mucosal margins in the larynx,...
Mauna Kea Technologies Secures Additional U.S. Artificial Intelligence Patent to Strengthen Endomicroscopy IP Complex
13th U.S. AI patent awarded to Mauna Kea Expanded patent portfolio boosts platform value, supports strategic partnerships Paris and Boston,...
Mauna Kea Technologies Reports Full Year 2024 Sales and Provides Strategic Update
Full Year Sales excluding licenses of €5.6m, down 9% YoY amid delayed capital sales and no revenue from JV in China Two specialized investment banks...
Mauna Kea Technologies Announces its 2025 Financial Calendar
Paris and Boston, January 14, 2025 – 5:45 p.m. CET – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary...
Raising Pancreatic Cancer Awareness Through Patient Voices
With its Needle-Based Confocal Laser Endomicroscopy Solution, Mauna Kea is Playing a Decisive Role in the Fight Against Pancreatic...
Mauna Kea Technologies Celebrates Over 700 Procedures Performed in 18 Months at IECED-OMNI Hospital in Ecuador
Paris and Boston, November 20, 2024 – 5:45 p.m. CET – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary...